| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2008: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
We herein report a new finding, namely, the anti-proliferate potential of MethylEGCG and attempt to clarify its mechanism of action against a Huh7 hepatoma cell line. inhibition by flow cytometry. MethylEGCG was found to induce cell proliferation at a very low concentration (5uM). The expression of pAkt was down-regulated after treatment at concentrations under 5uM. We observed the in vivo growth of a tumor graft model (5×10^6 Huh7 cells grafted in the skin of nude mice). The tumor growth of the 1mg/1kg MethylEGCG i.p and 7.5mg/kg MethylEGCG orally group showed a significant difference (after 2 weeks, vs. control ; p<0.05 and after 3 weeks, vs control ; p<0.01(n=12)). In summary, these findings suggest that MethylEGCG may be an important chemoprevention agent for the treatment of hepatoma.
|
